Clinical Management and research questions from the emerging spectrum of Inflammatory disorders associated with SARS-CoV 2. IPA Webinar

PIMS-TS study group UK: Elizabeth Whittacker, Alasdaire Bamford, Hermione Lyall, Julia Kenny, Jethro Herberg, Myrsini Kaforou, Chrissy Jones, Mike Levin

Rady Children’s Hospital San Diego- Jane Burns, Adriana tremoulet, Chisato Shimizu.

BATS study group. Ortensia vito, priyen Shah, TishamDe, Ruud Nijman Harsita Patel, Andre Mcardle, Clare Wilson, Aubrey Cunnington
In March 2020 as COVID19 evolved in UK Paediatricians noticed unusual Illness

- Severe illness admitted to paediatric ward, or PICU
- Varied presentations - prolonged fever, sore throat, headache, abdominal pain and vomiting, rash, conjunctivitis
- Some developed shock, organ dysfunction
- In common - ↑ CRP, ↑ Neutrophil, ↓ lymphocytes, ↑ D-Dimers
- Some -typical Kawasaki disease features
- Majority SARS-CoV-2 PCR negative

58 cases from 8 hospitals in England and systematically reviewed
Development of a case definition

- Case note review, data collated on a data base
- Panel of infectious diseases and PICU specialists
- Initial report only Included children admitted to HDU/PICU
- Exclusion of any other microbial cause, including bacterial sepsis, staphylococcal or streptococcal shock syndromes; infections associated with myocarditis such as enterovirus and Macrophage activation syndromes
- NHS UK alerted on 24 April emerging new disorder
PIMS-TS appear to be a month behind the COVID-19 peak in the population.

Laboratory Confirmed COVID-19 cases, London
Clinical presentations

• **50% shock, Myocardial involvement**

• **52% rash**
  - 45% conjunctivitis, 29% mucus membrane

• **53% abdominal involvement**

• **38% acute kidney injury,**

• Unlike adults - only 32% respiratory symptoms

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PIMS-TS all cases</td>
<td>58</td>
</tr>
<tr>
<td>Age, median (Range) year</td>
<td>9 (5.7-13)</td>
</tr>
<tr>
<td>Male</td>
<td>25 /58 (43)</td>
</tr>
<tr>
<td>Ethnicity</td>
<td></td>
</tr>
<tr>
<td>Black</td>
<td>22 /58 (38)</td>
</tr>
<tr>
<td>White</td>
<td>12 /58 (21)</td>
</tr>
<tr>
<td>Asian</td>
<td>18/58 (31)</td>
</tr>
<tr>
<td>Other</td>
<td>6/58 (10)</td>
</tr>
<tr>
<td>Clinical Features at Presentation</td>
<td></td>
</tr>
<tr>
<td>Shock</td>
<td>29/58 (50)</td>
</tr>
<tr>
<td>Diarrhoea</td>
<td>30.58 (52)</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>31/58 (53)</td>
</tr>
<tr>
<td>Rash</td>
<td>30/58 (52)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>26/58 (45)</td>
</tr>
<tr>
<td>Conjunctival injection</td>
<td>26/58 (45)</td>
</tr>
<tr>
<td>Headache</td>
<td>15 /58 (26)</td>
</tr>
<tr>
<td>Respiratory symptoms</td>
<td>12/58 (21)</td>
</tr>
<tr>
<td>Mucus membrane changes</td>
<td>17/58 (29)</td>
</tr>
<tr>
<td>Sore throat</td>
<td>6/58 (10)</td>
</tr>
<tr>
<td>Confusion</td>
<td>5/58 (9)</td>
</tr>
<tr>
<td>Lymphadenopathy</td>
<td>9/58 (16)</td>
</tr>
<tr>
<td>Swollen hands and feet</td>
<td>9/58 (16)</td>
</tr>
</tbody>
</table>

**3 Groups**

• **Shock**
• **Kawasaki disease definition**
• **Fever and inflammation**
Inflammation and cardiac Injury

- Striking elevation of CRP, Ferritin, D Dimers, Fibrinogen

- Anaemia, Low Lymphocytes, low albumin

- Elevated Troponin and Pro-BNP
Case definition:

1. A child presenting with persistent fever, inflammation (neutrophilia, elevated CRP and lymphopenia) and evidence of single or multi-organ dysfunction (shock, cardiac, respiratory, renal, gastrointestinal or neurological disorder) with additional features [see listed in Appendix 1]). This may include children fulfilling full or partial criteria for Kawasaki disease.

2. Exclusion of any other microbial cause, including bacterial sepsis, staphylococcal or streptococcal shock syndromes, infections associated with myocarditis such as enterovirus (waiting for results of these investigations should not delay seeking expert advice).

3. SARS-CoV-2 PCR testing may be positive or negative

---

Emergency Preparedness and Response

Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with Coronavirus Disease 2019 (COVID-19) May 14, 2020

Case Definition for Multisystem Inflammatory Syndrome in Children (MIS-C)

- An individual aged <21 years presenting with fever, laboratory evidence of inflammation, and evidence of clinically severe illness requiring hospitalization, with multisystem (≥2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic or neurological); AND
- No alternative plausible diagnoses; AND
- Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test; or COVID-19 exposure within the 4 weeks prior to the onset of symptoms

Fever ≥38.0°C for ≥24 hours, or report of subjective fever lasting ≥24 hours

Including, but not limited to, one or more of the following: an elevated C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fibrinogen, procalcitonin, d-dimer, ferritin, lactate dehydrogenase (LDH), or interleukin 6 (IL-6), elevated neutrophils, reduced lymphocytes and low albumin
Multisystem inflammatory syndrome in children and adolescents with COVID-19

Scientific brief
15 May 2020

Preliminary case definition*

Children and adolescents 0–19 years of age with fever ≥ 3 days

AND two of the following:

a) Rash or bilateral non-purulent conjunctivitis or muco-cutaneous inflammation signs (oral, hands or feet).

b) Hypotension or shock.

c) Features of myocardial dysfunction, pericarditis, valvulitis, or coronary abnormalities (including ECHO findings or elevated Troponin/NT-proBNP),

d) Evidence of coagulopathy (by PT, PTT, elevated d-Dimers).

e) Acute gastrointestinal problems (diarrhoea, vomiting, or abdominal pain).

AND

Elevated markers of inflammation such as ESR, C-reactive protein, or procalcitonin.

AND

No other obvious microbial cause of inflammation, including bacterial sepsis, staphylococcal or streptococcal shock syndromes.

AND

Evidence of COVID-19 (RT-PCR, antigen test or serology positive), or likely contact with patients with COVID-19.
An emerging new spectrum of SARS-CoV2 in children

COVID 19 in children: generally mild or asymptomatic

POST SARS-CoV2 Inflammatory syndromes

- MIS-C
- MIS-C
- WHO
- PIMS-TS
- KD-TS
- Fever and Inflammation-TS

Paediatric Inflammatory multisystem Syndrome temporally associated with SARS-CoV2
Kawasaki disease-Temporally associated with SARS-CoV2
Febrile Children with Inflammation-Temporally associated with SARS-CoV2
Do we need proof of Previous or current SARS COv2: No clinical or Laboratory differences between SARS Cov2 positive and unknown patients
What is this new disease?

It’s a Fan!

It’s Kawasaki

It’s a Wall!

It’s TSS

Its cytokine storm

How do we treat it?
Kawasaki disease, Kawasaki shock syndrome, and Toxic Shock syndrome have clear differences from PIMS-TS.

Comparison of PIMS-TS (UK) with >1000 Kawasaki disease patients (SanDiego) and KD shock and TSS.

Clear differences:

We cannot assume the same treatments for KD will work in PIMS/MIS.
SARS-CoV2 Infection

Mild infection in Children/adults with "normal immune response"

abnormal Immune response
Production of disease enhancing non neutralizing antibodies/T cells

1-4 weeks after infection

Delayed inflammation in adults with severe disease

Febrile children with elevated Inflammatory markers FI-TS

SARS-CoV2 Infection

KD-TS
KD and inflammation in febrile children. ?genetics

PIMS-TS
delayed inflammation and organ injury as acquired immunity develops?

Platelet immune complex interaction in pathogenesis of Kawasaki disease and childhood polyarteritis

MICHAEL LEVIN, PHILIP C HOLLAND, TIM J C NORES, VALERIO NOVELLI, MARTIN MOLA, ROLAND J LEVINSKY, MICHAEL J DILLON, T MARTIN BARRATT, WILLIAM C MARSHALL.
Clinical questions: Inflammation and Fever Temporally associated with SARS-CoV2

What is the risk of Coronary artery aneurysms

Febrile child With Inflammation

Inflammation Shock, Organ failure

“Kawasaki Disease”

What is the risk of progression to KD and Multiorgan failure?

Mild Symptomatic COVID
Treatment questions on Febrile Inflammation spectrum associated with SARS COV2

What is the risk of Coronary artery aneurysms?

Inflammation Shock, Organ failure

“Kawasaki Disease”

What TREATMENT prevents progression to KD and Multiorgan failure?

What Biomarkers predict progression?

Which treatment prevents Coronary artery aneurysms?

Mild Symptomatic COVID

Febrile child With Inflammation
Urgent Clinical Management question

• Do patients progress from the less severe to more serious categories? ie. Febrile inflammation $\rightarrow$ KD $\rightarrow$ PIMS/MIS-C

• What is the risk of Coronary artery aneurysms in each group?

• What is the relationship between KD-TS and KD prior to the pandemic? Are the mechanisms different.

• Do anti-inflammatory and immuno-modulating treatments such as immunoglobulin, steroids, anti-TNF, anti-IL1, anti-IL6 agents improve outcome AND reduce risk of coronary artery aneurysms?

• What treatment should be given in Less resourced countries

• What are the mechanism

• Are there biomarkers to distinguish each group(Febrile inflammation/KD/ PIMS) and COVID from other conditions
Can we identify patients at risk of progression to shock
What treatment should be given to prevent progression, prevent Coronary damage, improve outcome

- Pediatricians have used “Best Guess” of available treatments.

- We do not know which of the agents given have been beneficial or harmful

- Treatments for Kawasaki disease may or may not be optimal

- Need data to inform Practice

Unpublished 3 centre survey 134 patients courtesy Prof Alain Fraisse RBH
International study of Best available treatment for paediatric inflammatory syndromes associate with SARS-Cov-2- “Best available treatment( Do your Best study ).”

- Randomised trials are needed to resolve best therapy
- However patients in many countries presenting now
- Unlikely to have Randomised trials up and running in time to help clinicians decisions
- Over 1000 children already treated with Clinicians “Best guess”
- Many countries have shortages or no availability of IVIG or biologicals

- Can we use the data on children already treated- and those presenting now to answer the therapeutic questions, and inform the design of Randomised trials?
The hypothesis underlying this study

administration immunomodulating agents such as immunoglobulin, anti TNF, anti IL1, or anti IL6 therapies, will result in more rapid resolution of inflammatory markers, prevent progression from FIS-TS to KD-TS or PIMS-TS, reduce the need for intensive care or organ support and reduce coronary artery aneurysm rate and severity.

Although Not randomised Each Institution and clinician chose best treatment which can be compared if patients are matched for severity

Large numbers of patients

Modelled curve of rate of change of CRP (Ferritin, Troponin, BNP, D Dimers)

Corrected for severity, day of illness, age, level of marker at start of treatment
How to Participate?

• To enter the trial and provide data: log onto the online study entry site and provide contact details (email, address, country and institution). *(Live next week)*

bestavailabletreatmentstudy@gmail.com

Analysis

Electronically captured data following treatment with any of the agents will be analysed by the machine learning and data monitoring group at Imperial College who have expertise in application of machine learning techniques to large scale patient data.

Acknowledgement, participation and ownership of data

All clinicians submitting patients to this study will be listed as a member of the international consortium, have access to their own data for their own analyses and included in all subsequent reports.

Open to all countries
We also need to study the Biology of a new spectrum of diseases

• Detailed clinical phenotyping and sample collection is needed
• RNA, DNA, serum, Plasma, cells, post mortem tissue in acute stage and convalescence will enable:
  • Study of Genetics, Biomarkers of severity and diagnosis, immunopathology.

• Contribute to local studies

European Union’s Horizon 2020 research and innovation programme grant agreement no. 848196
THANKS

PIMS-TS study group UK: Elizabeth Whittacker, Alasdaire Bamford, Hermione Lyall, Julia Kenny, Jethro Herberg, Myrsini Kaforou, Chrissy Jones, Alain Frais, Owen Miller, Filip Kucera,

Rady Children’s Hospital San Diego- Jane Burns, Adriana tremoulet, Chisato Shimizu.
BATS study group. Ortensia Vito, Priyen Shah,TishamDe, Ruud Nijman Harsita Patel, Andre Mcardle, Clare Wilson, Aubrey Cunnington